Teryl K Nuckols1, Emmett Keeler2, Sally C Morton3, Laura Anderson4, Brian Doyle5, Marika Booth2, Roberta Shanman2, Jonathan Grein6, Paul Shekelle7. 1. Cedars-Sinai Medical Center, Los Angeles, California2RAND Corporation, Santa Monica, California. 2. RAND Corporation, Santa Monica, California. 3. College of Science, Virginia Tech, Blacksburg, Virginia. 4. Cedars-Sinai Medical Center, Los Angeles, California4Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles. 5. VA Greater Los Angeles Healthcare System, Los Angeles, California. 6. Cedars-Sinai Medical Center, Los Angeles, California. 7. RAND Corporation, Santa Monica, California5VA Greater Los Angeles Healthcare System, Los Angeles, California.
Abstract
IMPORTANCE: Although quality improvement (QI) interventions can reduce central-line-associated bloodstream infections (CLABSI) and catheter-related bloodstream infections (CRBSI), their economic value is uncertain. OBJECTIVE: To systematically review economic evaluations of QI interventions designed to prevent CLABSI and/or CRBSI in acute care hospitals. EVIDENCE REVIEW: A search of Ovid MEDLINE, Econlit, Centre for Reviews & Dissemination, New York Academy of Medicine's Grey Literature Report, Worldcat, prior systematic reviews (January 2004 to July 2016), and IDWeek conference abstracts (2013-2016), was conducted from 2013 to 2016. We included English-language studies of any design that evaluated organizational or structural changes to prevent CLABSI or CRBSI, and reported program and infection-related costs. Dual reviewers assessed study design, effectiveness, costs, and study quality. For each eligible study, we performed a cost-consequences analysis from the hospital perspective, estimating the incidence rate ratio (IRR) and incremental net savings. Unadjusted weighted regression analyses tested predictors of these measures, weighted by catheter-days per study per year. FINDINGS: Of 505 articles, 15 unique studies were eligible, together representing data from 113 hospitals. Thirteen studies compared Agency for Healthcare Research and Quality-recommended practices with usual care, including 7 testing insertion checklists. Eleven studies were based on uncontrolled before-after designs, 1 on a randomized controlled trial, 1 on a time-series analysis, and 2 on modeled estimates. Overall, the weighted mean IRR was 0.43 (95% CI, 0.35-0.51) and incremental net savings were $1.85 million (95% CI, $1.30 million to $2.40 million) per hospital over 3 years (2015 US dollars). Each $100 000-increase in program cost was associated with $315 000 greater savings (95% CI, $166 000-$464 000; P < .001). Infections and net costs declined when hospitals already used checklists or had baseline infection rates of 1.7 to 3.7 per 1000 catheter-days. Study quality was not associated with effectiveness or costs. CONCLUSIONS AND RELEVANCE: Interventions related to central venous catheters were, on average, associated with 57% fewer bloodstream infections and substantial savings to hospitals. Larger initial investments may be associated with greater savings. Although checklists are now widely used and infections have started to decline, additional improvements and savings can occur at hospitals that have not yet attained very low infection rates.
IMPORTANCE: Although quality improvement (QI) interventions can reduce central-line-associated bloodstream infections (CLABSI) and catheter-related bloodstream infections (CRBSI), their economic value is uncertain. OBJECTIVE: To systematically review economic evaluations of QI interventions designed to prevent CLABSI and/or CRBSI in acute care hospitals. EVIDENCE REVIEW: A search of Ovid MEDLINE, Econlit, Centre for Reviews & Dissemination, New York Academy of Medicine's Grey Literature Report, Worldcat, prior systematic reviews (January 2004 to July 2016), and IDWeek conference abstracts (2013-2016), was conducted from 2013 to 2016. We included English-language studies of any design that evaluated organizational or structural changes to prevent CLABSI or CRBSI, and reported program and infection-related costs. Dual reviewers assessed study design, effectiveness, costs, and study quality. For each eligible study, we performed a cost-consequences analysis from the hospital perspective, estimating the incidence rate ratio (IRR) and incremental net savings. Unadjusted weighted regression analyses tested predictors of these measures, weighted by catheter-days per study per year. FINDINGS: Of 505 articles, 15 unique studies were eligible, together representing data from 113 hospitals. Thirteen studies compared Agency for Healthcare Research and Quality-recommended practices with usual care, including 7 testing insertion checklists. Eleven studies were based on uncontrolled before-after designs, 1 on a randomized controlled trial, 1 on a time-series analysis, and 2 on modeled estimates. Overall, the weighted mean IRR was 0.43 (95% CI, 0.35-0.51) and incremental net savings were $1.85 million (95% CI, $1.30 million to $2.40 million) per hospital over 3 years (2015 US dollars). Each $100 000-increase in program cost was associated with $315 000 greater savings (95% CI, $166 000-$464 000; P < .001). Infections and net costs declined when hospitals already used checklists or had baseline infection rates of 1.7 to 3.7 per 1000 catheter-days. Study quality was not associated with effectiveness or costs. CONCLUSIONS AND RELEVANCE: Interventions related to central venous catheters were, on average, associated with 57% fewer bloodstream infections and substantial savings to hospitals. Larger initial investments may be associated with greater savings. Although checklists are now widely used and infections have started to decline, additional improvements and savings can occur at hospitals that have not yet attained very low infection rates.
Authors: Naomi P O'Grady; Mary Alexander; E Patchen Dellinger; Julie L Gerberding; Stephen O Heard; Dennis G Maki; Henry Masur; Rita D McCormick; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne Randolph; Robert A Weinstein Journal: Infect Control Hosp Epidemiol Date: 2002-12 Impact factor: 3.254
Authors: Chiun-Fang Chiou; Joel W Hay; Joel F Wallace; Bernard S Bloom; Peter J Neumann; Sean D Sullivan; Hsing-Ting Yu; Emmett B Keeler; James M Henning; Joshua J Ofman Journal: Med Care Date: 2003-01 Impact factor: 2.983
Authors: Nathorn Chaiyakunapruk; David L Veenstra; Benjamin A Lipsky; Sean D Sullivan; Sanjay Saint Journal: Clin Infect Dis Date: 2003-08-27 Impact factor: 9.079
Authors: Heidi L Frankel; William B Crede; Jeffrey E Topal; Sarah A Roumanis; Marie W Devlin; Andrea B Foley Journal: J Am Coll Surg Date: 2005-09 Impact factor: 6.113
Authors: Hend A Hanna; Issam I Raad; Brenda Hackett; Susannah K Wallace; Kristen J Price; D Elizabeth Coyle; C Lee Parmley Journal: Chest Date: 2003-09 Impact factor: 9.410
Authors: Sradha Kotwal; Sarah Coggan; Stephen McDonald; Girish Talaulikar; Alan Cass; Stephen Jan; Kevan R Polkinghorne; Nicholas A Gray; Martin Gallagher Journal: Kidney360 Date: 2020-06-02
Authors: Sara G McCleskey; Lili Shek; Jonathan Grein; Hiroshi Gotanda; Laura Anderson; Paul G Shekelle; Emmett Keeler; Sally Morton; Teryl K Nuckols Journal: BMJ Qual Saf Date: 2021-11-25 Impact factor: 7.418
Authors: Teryl K Nuckols; Emmett Keeler; Laura J Anderson; Jonas Green; Sally C Morton; Brian J Doyle; Kanaka Shetty; Aziza Arifkhanova; Marika Booth; Roberta Shanman; Paul Shekelle Journal: Diabetes Care Date: 2018-05 Impact factor: 17.152
Authors: Mitchell S von Itzstein; Arjun Gupta; Kemp H Kernstine; Kristin C Mara; Sahil Khanna; David E Gerber Journal: PLoS One Date: 2020-04-09 Impact factor: 3.240
Authors: Sradha Kotwal; Alan Cass; Sarah Coggan; Nicholas A Gray; Stephen Jan; Stephen McDonald; Kevan R Polkinghorne; Kris Rogers; Girish Talaulikar; Gian Luca Di Tanna; Martin Gallagher Journal: BMJ Date: 2022-04-12